ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Vielight Unveils the First Photobiomodulation-Based Vagus Nerve Stimulation Device Following Patent Approval

Toronto, Ontario, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Toronto, ON — Vielight Inc., a leader in photobiomodulation (PBM) technologies, is pleased to announce the issuance of a utility patent for its device, the Vielight Vagus . This cutting-edge device marks the first PBM-based vagus nerve stimulation (VNS) system designed for trans-cervical application, paving the way for new therapeutic opportunities across a variety of sectors.

The Vielight Vagus represents a next-generation, non-invasive VNS modality that combines the safety and bioenergetic advantages of PBM with the benefits of cervical vagus nerve stimulation. Compared to auricular or electrical cervical methods, it offers a comfortable, gel-free, and sensation-free experience with promising potential for autonomic and systemic benefits. Its bilateral, 100-Hz pulsed approach, grounded in emerging science, provides an innovative path for heart-rate variability (HRV) modulation and neurophysiological enhancement. The device’s usability supports integration into home-based clinical research. VNS applications will be a focus of Vielight’s future investigations.

The vagus nerve is essential in regulating critical bodily functions, including mood, inflammation control, and overall homeostasis. Current methods of vagus-nerve stimulation often involve invasive surgical procedures or electrical approaches that can present challenges related to safety and user comfort. The Vielight Vagus offers a non-invasive alternative by utilizing pulsed near-infrared light, specifically targeting the cervical branches of the vagus nerve, coupled with intranasal application supported by evidence of systemic effects.

“Our mission at Vielight is to harness the power of light to enhance human health and well-being. With the Vielight Vagus, we are introducing a more user-friendly and accessible approach for managing autonomic balance, reducing systemic inflammation, and potentially improving mental health,” said Dr. Lew Lim, CEO of Vielight Inc. “This patent approval is a significant milestone not only for our company but for individuals seeking non-invasive wellness solutions.”

The Vielight Vagus device is designed for easy home use, featuring a hands-free, battery-powered collar that ensures consistent anatomical placement for optimal targeting. Preliminary experimental outcomes indicate a notable increase in vagal tone at specific pulse frequencies, aligning with findings from existing electrical VNS research.

As a low-risk, general-wellness device, Vielight is not making direct medical claims regarding the Vielight Vagus. Clinical efficacy claims will be made only following rigorous studies and the necessary regulatory approvals.

For more information about the Vielight Vagus and to stay updated on clinical studies and scientific advancements, please visit: https://www.vielight.com/devices/vagus/
To view the patent details (PDF): https://www.vielight.com/wp-content/uploads/2023/12/Vielight-Vagus-Patent.pdf

Media Contact
Vielight Inc.
Peter Adams
VP, Sales and Marketing
peteradams@vielight.com
+1-416-710-7140

About Vielight Inc.
Vielight Inc. is dedicated to advancing health and wellness through innovative photobiomodulation technology. We aim to provide non-invasive solutions that enhance quality of life and foster autonomy in health management.

Available for interview: Dr. Lew Lim

Attachments


Peter Adams
Vielight Inc.
+1-416-710-7140
peteradams@vielight.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.